Cocetta Veronica, Giacomini Isabella, Tinazzi Mattia, Berretta Massimiliano, Quagliariello Vincenzo, Maurea Nicola, Ragazzi Eugenio, Carnevali Ilaria, Montopoli Monica
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Minerva Pediatr (Torino). 2023 May 11. doi: 10.23736/S2724-5276.23.07128-8.
Irritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD) are pathological conditions that severely hamper the quality of life of patients. Especially in pediatric and adolescent patients, the use of Complementary and alternative medicine is an appealing approach as an adjuvant for the management of symptoms, limiting the detrimental effect of the conventional therapy. In this work, we tested the effect of Enterokind Junior (EntJ), a mix of two probiotic strains Lactobacillus reuteri DSM 25175 and Lactobacillus acidophilus DSM 24936, Matricaria Chamomilla, and vitamins, in in vitro model of intestinal inflammation. Caco-2 cells were subjected to LPS treatment or THP-1 cells stimulated with LPS treatment, as paradigms of inflammatory conditions.
The effect of the probiotic formulation was evaluated by measuring Caco-2 monolayer's Transepithelial Electrical resistance (TEER) and paracellular permeability alterations, tight junction proteins expression and localization by confocal microscopy, and release of pro-inflammatory cytokines (TNF-α and IL-8) by ELISA assay.
Results demonstrated that upon impairment of intestinal parameters induced by inflammatory stimuli, the combination of probiotic was able to prevent TEER decrease and paracellular permeability alterations and to maintain the tight junction expression and localization. Moreover, the release of proinflammatory cytokines induced by inflammation was reduced by EntJ treatment.
This work, in line with previous observations, supports a protective role of Lactobacillus reuteri DSM 25175, Lactobacillus acidophilus DSM 24936 and the other components in the maintenance of a healthy gut, holding up the use of this combination as an adjuvant for irritable bowel syndrome-related symptoms management.
肠易激综合征（IBS）和炎症性肠病（IBD）是严重影响患者生活质量的病理状况。特别是在儿科和青少年患者中，使用补充和替代医学作为辅助手段来管理症状，限制传统疗法的有害影响，是一种有吸引力的方法。在这项研究中，我们测试了肠乐健Junior（EntJ）的效果，它是两种益生菌菌株罗伊氏乳杆菌DSM 25175和嗜酸乳杆菌DSM 24936、母菊花和维生素的混合物，在肠道炎症的体外模型中进行了测试。将Caco-2细胞进行LPS处理，或将THP-1细胞用LPS处理进行刺激，作为炎症状态的范例。
通过测量Caco-2单层的跨上皮电阻（TEER）和细胞旁通透性改变、共聚焦显微镜检测紧密连接蛋白的表达和定位，以及ELISA法检测促炎细胞因子（TNF-α和IL-8）的释放，来评估益生菌制剂的效果。
结果表明，在炎症刺激引起肠道参数受损后，益生菌组合能够防止TEER降低和细胞旁通透性改变，并维持紧密连接的表达和定位。此外，EntJ处理可减少炎症诱导的促炎细胞因子的释放。
这项研究与之前的观察结果一致，支持罗伊氏乳杆菌DSM 25175、嗜酸乳杆菌DSM 24936和其他成分在维持健康肠道方面的保护作用，支持将这种组合用作肠易激综合征相关症状管理的辅助手段。
